|
Mergers and acquisitions are all too common for pharmaceutical manufacturers. While the combination of two companies has its benefits, it doesn’t come without growing pains and challenges. Take, for example, labelling. A merger can result in decentralised labelling processes with inherited home-grown systems and a new array of third-party suppliers, contract manufacturers, re-packagers, and re-labellers. It can also lead to expansion into new geographic markets; each with their own country-specific labelling requirements.
As growing pharma manufacturers work to address these challenges, the importance of label accuracy can’t be understated.
A decentralised approach to labelling makes achieving label accuracy and consistency a complex task that can be a major threat to profitability, drag down efficiency, reduce agility, and impact speed-to-market.
|
